Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada
School of Pharmacy, Faculty of Medicine and Health, and Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
BMJ Qual Saf. 2022 Mar;31(3):179-190. doi: 10.1136/bmjqs-2021-013910. Epub 2022 Jan 20.
To evaluate the association between regulatory drug safety advisories and changes in drug utilisation.
We conducted controlled, interrupted times series analyses with administrative prescription claims data to estimate changes in drug utilisation following advisories. We used random-effects meta-analysis with inverse-variance weighting to estimate the average postadvisory change in drug utilisation across advisories.
We included advisories issued in Canada, Denmark, the UK and the USA during 2009-2015, mainly concerning drugs in common use in primary care. We excluded advisories related to over-the-counter drugs, drug-drug interactions, vaccines, drugs used primarily in hospital and advisories with co-interventions within ±6 months.
Change in drug utilisation, defined as actual versus predicted percentage change in the number of prescriptions (for advisories without dose-related advice), or in the number of defined daily doses (for dose-related advisories), per 100 000 population.
Among advisories without dose-related advice (n=20), the average change in drug utilisation was -5.83% (95% CI -10.93 to -0.73; p=0.03). Advisories with dose-related advice (n=4) were not associated with a statistically significant change in drug utilisation (-1.93%; 95% CI -17.10 to 13.23; p=0.80). In a post hoc subgroup analysis of advisories without dose-related advice, we observed no statistically significant difference between the change in drug utilisation following advisories with explicit prescribing advice, such as a recommendation to consider the risk of a drug when prescribing, and the change in drug utilisation following advisories without such advice.
Among safety advisories issued on a wide range of drugs during 2009-2015 in 4 countries (Canada, Denmark, the UK and the USA), the association of advisories with changes in drug utilisation was variable, and the average association was modest.
评估监管药品安全通告与药物使用变化之间的关联。
我们使用行政处方索赔数据进行对照、中断时间序列分析,以估计通告后药物使用的变化。我们使用具有逆方差加权的随机效应荟萃分析来估计通告间药物使用变化的平均后效。
我们纳入了 2009-2015 年期间在加拿大、丹麦、英国和美国发布的通告,主要涉及初级保健中常用的药物。我们排除了与非处方药物、药物相互作用、疫苗、主要在医院使用的药物以及通告中在 ±6 个月内存在联合干预的通告。
药物使用变化,定义为每 10 万人实际处方数量(对于没有剂量相关建议的通告)或定义日剂量数量(对于剂量相关通告)的变化百分比与预测百分比的差异。
在没有剂量相关建议的通告中(n=20),药物使用变化的平均值为-5.83%(95% CI-10.93 至-0.73;p=0.03)。有剂量相关建议的通告(n=4)与药物使用变化之间没有统计学显著关联(-1.93%;95% CI-17.10 至 13.23;p=0.80)。在没有剂量相关建议的通告的事后亚组分析中,我们没有观察到具有明确处方建议的通告(如在开处方时考虑药物风险的建议)和没有此类建议的通告后药物使用变化之间存在统计学显著差异。
在 2009-2015 年期间在 4 个国家(加拿大、丹麦、英国和美国)发布的广泛的药物安全通告中,通告与药物使用变化之间的关联是可变的,平均关联程度较弱。